Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents.
Dean
N M
NM
Department of Molecular Pharmacology, ISIS Pharmaceuticals, Carlsbad, CA 92008, USA.
McKay
R
R
Miraglia
L
L
Geiger
T
T
Müller
M
M
Fabbro
D
D
Bennett
C F
CF
D000818:Animals; D002986:Clinical Trials as Topic; D046508:Culture Techniques; D018390:Gene Targeting; D006801:Humans; D007527:Isoenzymes / Q000235:genetics; D016376:Oligonucleotides, Antisense / Q000235:genetics / Q000493:pharmacokinetics / Q000494:pharmacology*; D011493:Protein Kinase C / Q000235:genetics; D051571:Protein Kinase C-alpha; D017346:Protein Serine-Threonine Kinases / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000235:genetics; D019908:Proto-Oncogene Proteins c-raf; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects* / Q000235:genetics
D007527:Isoenzymes; D016376:Oligonucleotides, Antisense; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D017346:Protein Serine-Threonine Kinases; D019908:Proto-Oncogene Proteins c-raf; C496628:PRKCA protein, human; D011493:Protein Kinase C; D051571:Protein Kinase C-alpha